Physicochemical characterisation of the oligosaccharide component of vaccines.
Glycoconjugate vaccines are being developed against Haemophilus influenzae (Hib) and meningococcal Type A and C micro-organisms; they consist of oligosaccharides of intermediate chain length conjugated to the carrier protein CRM (a non-toxic diphtheria toxin mutant). The oligosaccharides can be quantified using specific composition analyses and their structure and identity (and pattern of acetylation) evaluated by use of NMR spectroscopy. The average molecular-size (degree of polymerisation) can be determined using colorimetric assays, qualified by analysis of authentic standards. The molecular-size distribution of these anionic oligosaccharides can be achieved using ion exchange chromatography or application of the rapid and sensitive analytical HPAEC-PAD system (high performance anion-exchange chromatography with pulsed amperometric detection). Preparative ion exchange chromatography permits the isolation of purified oligomers, which can be well-characterised using the methods described above. Molecular size can be confirmed by use of mass spectrometry. These vaccines are semi-synthetic products and therefore their preparation involves several steps of chemical reaction, the detailed physicochemical characterisation of the oligosaccharide-components permits the consistent production of these well-defined glycoconjugate vaccines.
Ravenscroft
N
N
Chiron Vaccines, Siena, Italy.
D'Ascenzi
S
S
Proietti
D
D
Norelli
F
F
Costantino
P
P
D055598:Chemical Phenomena; D002627:Chemistry, Physical; D002852:Chromatography, Ion Exchange; D003124:Colorimetry; D006023:Glycoproteins / Q000276:immunology; D009682:Magnetic Resonance Spectroscopy; D008970:Molecular Weight; D009844:Oligosaccharides / Q000737:chemistry*; D014612:Vaccines / Q000737:chemistry*
D006023:Glycoproteins; D009844:Oligosaccharides; D014612:Vaccines